Page 110 - 2019_09-HaematologicaMondo-web

M. Robin et al.
Blood Marrow Transplant. 2010;16(3):358-
367.
10. Robin M, Tabrizi R, Mohty M, et al.
Allogeneic haematopoietic stem cell trans- plantation for myelofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Br J Haematol. 2011;152(3):331-339.
11. Gupta V, Malone AK, Hari PN, et al. Reduced-intensity hematopoietic cell trans- plantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2014;20(1):89-97.
12. Rondelli D, Goldberg JD, Isola L, et al. MPD- RC 101 prospective study of reduced-inten- sity allogeneic hematopoietic stem cell transplantation in patients with myelofibro- sis. Blood. 2014;124(7):1183-1191.
13. Ditschkowski M, Elmaagacli AH, Trenschel R, et al. Dynamic International Prognostic Scoring System scores, pre-transplant thera- py and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis. Haematologica. 2012;97(10): 1574-1581.
14. Deeg HJ, Gooley TA, Flowers MED, et al. Allogeneic hematopoietic stem cell trans- plantation for myelofibrosis. Blood. 2003; 102(12):3912-3918.
15. Scott BL, Gooley TA, Sorror ML, et al. The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation. Blood. 2012;119(11):2657-2664.
16. Samuelson Bannow BT, Salit RB, Storer BE, et al. Hematopoietic Cell Transplantation for Myelofibrosis: the Dynamic International Prognostic Scoring System Plus Risk Predicts Post-Transplant Outcomes. Biol Blood Marrow Transplant. 2018;24(2): 386-392.
17. Kröger N, Giorgino T, Scott BL, et al. Impact
of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis. Blood. 2015;125(21):3347-3350; quiz 3364.
18. Cervantes F, Pereira A. Does ruxolitinib pro- long the survival of patients with myelofi- brosis? Blood. 2017;129(7):832-837.
19. Socié G, Stone JV, Wingard JR, et al. Long- term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med. 1999;341(1):14-21.
20. Wingard JR, Majhail NS, Brazauskas R, et al. Long-term survival and late deaths after allo- geneic hematopoietic cell transplantation. J Clin Oncol. 2011;29(16):2230-2239.
21. Goldman JM, Majhail NS, Klein JP, et al. Relapse and late mortality in 5-year sur- vivors of myeloablative allogeneic hematopoietic cell transplantation for chron- ic myeloid leukemia in first chronic phase. J Clin Oncol. 2010;28(11):1888-1895.
22. Martin PJ, Counts GW, Appelbaum FR, et al. Life expectancy in patients surviving more than 5 years after hematopoietic cell trans- plantation. J Clin Oncol. 2010;28(6):1011- 1016.
23. Bhatia S, Francisco L, Carter A, et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood. 2007;110(10):3784-3792.
24. van Gelder M, de Wreede LC, Bornhäuser M, et al. Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2017;52(3):372-380.
25. Iacobelli S; EBMT Statistical Committee. Suggestions on the use of statistical method- ologies in studies of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2013;48 Suppl 1S1-37.
26. Pohar Perme M, Estève J, Rachet B. Analysing population-based cancer survival - settling the controversies. BMC Cancer. 2016;16(1):933.
27. Schetelig J, de Wreede LC, van Gelder M, et al. Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syn- dromes and secondary acute myeloid leukemia. Leukemia. 2019;33(3):686-695.
28. Pophali PA, Klotz JK, Ito S, et al. Male sur- vivors of allogeneic hematopoietic stem cell transplantation have a long term persisting risk of cardiovascular events. Exp Hematol. 2014;42(2):83-89.
29. Shimoni A, Labopin M, Savani B, et al. Long-term survival and late events after allo- geneic stem cell transplantation from HLA- matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation. J Hematol Oncol. 2016;9 (1):118.
30. Robin M, Porcher R, De Castro Araujo R, et al. Risk factors for late infections after allo- geneic hematopoietic stem cell transplanta- tion from a matched related donor. Biol Blood Marrow Transplant. 2007;13(11): 1304-1312.
31. Syrjala KL, Martin PJ, Lee SJ. Delivering care to long-term adult survivors of hematopoiet- ic cell transplantation. J Clin Oncol. 2012; 30(30):3746-3751.
32. Majhail NS, Rizzo JD, Lee SJ, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Rev Bras Hematol Hemoter. 2012;34(2):109-133.
33. Bhatia S, Armenian SH, Landier W. How I monitor long-term and late effects after blood or marrow transplantation. Blood. 2017;130(11):1302-1314.
1788
haematologica | 2019; 104(9)